FGF basic

FGF basic

FGF basic Overview

Molecule Name
Fibroblast growth factor 2
Synonyms
FGF2,BFGF,FGFB,FGF basic,HBGF-2
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs1
Highest Development StageApproved
Target Synonym
FGF-2,Heparin-binding growth factor 2,Basic fibroblast growth factor,FGFB,bFGF,HBGF-2,FGF2,Fibroblast Growth Factor 2 (Basic),Basic Fibroblast Growth Factor BFGF,Prostatropin,Fibroblast Growth Factor 2
Background
FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

FGF basic Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Muparfostat sodiumPI-88Phase 3 ClinicalAustralian National University
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Skin Melanoma; Solid tumours
Details
RBM-007ID3 (21); APT-F2; RBM-007Phase 2 ClinicalRibomic
Achondroplasia; Macular Degeneration
Details
Fibroblast growth factor 2 gene therapy (ID Pharma)SeV-10101; SEV-10101; DVC-10101; BF-30Phase 2 ClinicalDnavec
Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders
Details
Recombinant Human Epidermal Growth Factor Derivative Gel (Uni-Bio Science)Phase 1 ClinicalUni-Bio Science Group
Wounds and Injuries
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
ThalidomideNSC-66847; NSC-527179; K-17; FPF-300; FPF300ApprovedCelgene CorpTalizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, ThaledMainland ChinaLeprosy, Lepromatous; Multiple MyelomaChangzhou Pharmaceutical Factory1982-01-01
Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms
Details